VXRT
Vaxart, Inc.
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Last price
0.52
■ 0.00 (0.00%)
MARKET · —
Price
Open
0.52
Prev close
0.52
Day high
0.55
Day low
0.50
Volume
172.83K
Market cap
$126.27M
P/E (TTM)
3.06
52W range
0.31 – 0.84
Trailing performance
Returnvs SPY
1W
-3.70%
-2.3%
1M
+4.00%
+0.3%
3M
-23.53%
-26.6%
6M
-11.86%
-22.9%
YTD
+48.57%
+36.3%
1Y
+44.44%
+24.4%
3Y
-25.71%
-99.9%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$126.27M
Enterprise value$73.62M
Revenue (TTM)$243.06M
Gross profit$58.80M
EBITDA$45.62M
Net income$38.59M
EPS (TTM)$0.17
Free cash flow$-17.15M
Total cash$63.98M
Total debt$12.54M
Book value / share$0.39
Shares outstanding242.84M
Float239.24M
Short % of float9.40%
Dividend yield—
Beta (5Y)1.07
Valuation & profitability ratios
Trailing P/E3.06
Forward P/E-0.50
PEG ratio—
Price / sales—
Price / book1.33
EV / revenue0.30
EV / EBITDA1.61
Gross margin24.19%
Operating margin-48.45%
Profit margin15.88%
Return on equity66.97%
Return on assets15.04%
Debt / equity15.22
Current ratio1.60
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $237.26M | $28.70M | $7.38M | $107.00K |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $16.33M | -$66.95M | -$82.47M | -$107.76M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $16.33M | -$66.95M | -$82.47M | -$107.76M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.21 | -0.06 | +71.4% |
| Mar 2026 | 0.02 | 0.02 | 0.0% |
| Dec 2025 | -0.08 | 0.24 | +400.0% |
| Sep 2025 | -0.07 | -0.04 | +38.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.31 | 1 | $27.20M | -62.4% |
| Next quarter | -0.19 | 1 | $25.00M | -76.0% |
| Current year | -0.68 | 1 | $118.60M | -50.0% |
| Next year | -1.03 | 1 | $2.35M | -98.0% |
Analyst targets & ownership
Mean target$3.33
High target$4.00
Low target$2.00
Implied upside541.03%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders1.39%
Held by institutions0.05%
Institutions holding7
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.37M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 16, 26 | HERON ELAINE J Director |
— | 39.40K | — | Direct |
| Jul 16, 26 | BREITMEYER JAMES B Director |
— | 8.31K | — | Direct |
| Jul 16, 26 | WATSON WILLIAM MARK Director |
— | 39.40K | — | Direct |
| Jul 16, 26 | WHEADON DAVID E. Director |
— | 39.40K | — | Direct |
| Jul 16, 26 | FINNEY KEVIN Director |
— | 39.40K | — | Direct |
| May 22, 26 | WATSON WILLIAM MARK Director |
BUY | 10.00K | $6.53K | Direct |
| Apr 23, 26 | BREITMEYER JAMES B Director |
— | 78.80K | — | Direct |
| Mar 16, 26 | LO STEVEN Chief Executive Officer |
— | 846.50K | — | Direct |
| Mar 16, 26 | TUCKER SEAN N. Officer |
— | 200.00K | — | Direct |
| Mar 16, 26 | CUMMINGS JAMES F. Officer |
— | 227.00K | — | Direct |
| Mar 16, 26 | BERG EDWARD B General Counsel |
— | 115.00K | — | Direct |
| Mar 16, 26 | GRASMAN JEROEN NICOLAAS Chief Financial Officer |
— | 227.00K | — | Direct |
| Dec 4, 25 | LO STEVEN Chief Executive Officer |
— | 151.35K | — | Direct |
| Nov 17, 25 | HERON ELAINE J Director |
BUY | 40.00K | $15.92K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BERG EDWARD B |
General Counsel | 799.86K | Stock Award(Grant) |
CUMMINGS JAMES F. |
Officer | 964.79K | Stock Award(Grant) |
FINNEY KEVIN |
Director | 244.17K | Stock Award(Grant) |
FINNEY MICHAEL JOSEPH |
Director | 702.84K | Stock Award(Grant) |
GRASMAN JEROEN NICOLAAS |
Chief Financial Officer | 577.00K | Stock Award(Grant) |
HERON ELAINE J |
Director | 135.97K | Stock Award(Grant) |
LEE PHILLIP E. |
Chief Financial Officer | 631.62K | Stock Award(Grant) |
LO STEVEN |
Chief Executive Officer | 2.73M | Stock Award(Grant) |
TUCKER SEAN N. |
Officer | 991.75K | Stock Award(Grant) |
WATSON WILLIAM MARK |
Director | 173.53K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.53
-2.44% from price
SMA 20
0.54
-2.89% from price
SMA 50
0.54
-4.09% from price
SMA 100
0.61
-14.68% from price
SMA 200
0.57
-8.84% from price
EMA 12
0.53
-1.49% from price
EMA 26
0.54
-2.96% from price
EMA 50
0.55
-5.97% from price
RSI (14)
46.2
Neutral
MACD (12,26,9)
-0.01
Hist -0.00
ATR (14)
0.05
10.44% of price
Realised vol 30D
72.0%
Annualised
Bollinger upper
0.62
20, 2σ
Bollinger lower
0.45
20, 2σ
50 / 200 cross
Death
0.54 vs 0.57
Trend bias
Below 200
-8.84%
Risk profile
Beta vs SPY
0.75
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
72.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-43.8%
Peak to trough
Max drawdown 5Y
-96.7%
Peak to trough
ATR 14
0.05
10.44% of price
Beta (reported)
1.07
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...
GuruFocus.com · 12d ago
Vaxart Q2 Earnings Call Highlights
MarketBeat · 13d ago
Vaxart, Inc. Q2 2026 Earnings Call Summary
Moby · 15d ago
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
GlobeNewswire · 16d ago
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
GlobeNewswire · 23d ago
Vaxart to Participate in BTIG Biotechnology Conference 2026
GlobeNewswire · 32d ago
Vaxart Investors Reject Say-on-Pay as CEO Rules Out Reverse Split for Now
MarketBeat · 33d ago
Vaxart Announces Results of Annual Meeting of Stockholders
GlobeNewswire · 36d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.